These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33034902)

  • 61. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
    Visentin A; Imbergamo S; Trimarco V; Pravato S; Romano Gargarella L; Frezzato F; Scapinello G; Bertorelle R; Piva E; Facco M; Semenzato G; Piazza F; Trentin L
    Hematol Oncol; 2020 Dec; 38(5):823-826. PubMed ID: 32979282
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
    Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Successful treatment with silver nitrate chemical cauterization for paronychia and granulation in a patient with chronic lymphocytic leukemia undergoing ibrutinib therapy].
    Sato N; Yuda J; Yamauchi N; Kuzume A; Nakamura H; Chi S; Nagata A; Kaku E; Nishizawa A; Minami Y
    Rinsho Ketsueki; 2021; 62(1):35-41. PubMed ID: 33551423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.
    Khan Y; Lyou Y; El-Masry M; O'Brien S
    Expert Rev Hematol; 2020 Jan; 13(1):31-38. PubMed ID: 31756301
    [No Abstract]   [Full Text] [Related]  

  • 68. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
    [No Abstract]   [Full Text] [Related]  

  • 70. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.
    Visentin A; Compagno N; Cinetto F; Imbergamo S; Zambello R; Piazza F; Semenzato G; Trentin L; Agostini C
    Haematologica; 2015 Dec; 100(12):e515-8. PubMed ID: 26294735
    [No Abstract]   [Full Text] [Related]  

  • 71. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
    Levin MD; Kater AP; Mattsson M; Kersting S; Ranti J; Thi Tuyet Tran H; Nasserinejad K; Niemann CU
    BMJ Open; 2020 Oct; 10(10):e039168. PubMed ID: 33060089
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
    N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
    Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J
    Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
    Jain P; Keating M; Wierda W; Estrov Z; Ferrajoli A; Jain N; George B; James D; Kantarjian H; Burger J; O'Brien S
    Blood; 2015 Mar; 125(13):2062-7. PubMed ID: 25573991
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.
    Mozas P; Rivas-Delgado A; Baumann T; Villamor N; Ortiz-Maldonado V; Aymerich M; Costa D; Navarro A; Giné E; López-Guillermo A; Montserrat E; Delgado J
    Blood Cancer J; 2018 Jan; 8(1):10. PubMed ID: 29339727
    [No Abstract]   [Full Text] [Related]  

  • 76. UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
    Allain EP; Rouleau M; Vanura K; Tremblay S; Vaillancourt J; Bat V; Caron P; Villeneuve L; Labriet A; Turcotte V; Le T; Shehata M; Schnabl S; Demirtas D; Hubmann R; Joly-Beauparlant C; Droit A; Jäger U; Staber PB; Lévesque E; Guillemette C
    Br J Cancer; 2020 Jul; 123(2):240-251. PubMed ID: 32418995
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.
    UK CLL Forum
    Haematologica; 2016 Dec; 101(12):1563-1572. PubMed ID: 27756834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
    Solman IG; Blum LK; Hoh HY; Kipps TJ; Burger JA; Barrientos JC; O'Brien S; Mulligan SP; Kay NE; Hillmen P; Byrd JC; Lal ID; Dean JP; Mongan A
    Leuk Res; 2020 Oct; 97():106432. PubMed ID: 32911375
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.